210 filings
Page 2 of 11
8-K
vqq3juao5 ljng
4 Aug 22
GeoVax Reports 2022 Second Quarter Financial Results
4:06pm
8-K
ox1qpj05
27 May 22
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
4:48pm
8-K
9pde 4q59ft
2 May 22
GeoVax Reports 2022 First Quarter Financial Results
7:30am
8-K
7q8netkzfnp71m6
10 Mar 22
GeoVax Reports 2021 Year-End Financial Results
5:02pm
8-K
7zopuy2diq
20 Jan 22
GeoVax Announces $10 Million Private Placement
4:30pm
8-K
9lbinfd maawdibxa
4 Jan 22
GeoVax Issues Shareholder Update Letter
5:14pm
8-K
9tab5sc7r6gbjk8tv
15 Dec 21
GeoVax Announces Initiation of Phase 2 Clinical Trial
4:11pm
8-K
lecf9h9f z8
12 Nov 21
GeoVax Reports 2021 Third Quarter Financial Results
1:37pm
8-K
hoi3o 25r0jpe
10 Nov 21
GeoVax and City of Hope Announce Agreement to
4:41pm
8-K
jp37a6xx
30 Sep 21
GeoVax Gedeptin License Announcement Call
4:05pm
8-K
t7zocp94 c7u
29 Sep 21
Entry into a Material Definitive Agreement
4:15pm
8-K
655axoz1vbfw
20 Aug 21
GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly
9:00am
8-K
fbeysn
11 Aug 21
GeoVax Reports 2021 Second Quarter Financial Results
4:30pm
8-K
mdfeyl 8t
7 May 21
GeoVax Reports 2021 First Quarter Financial Results
1:05pm
8-K
6vbkdewsyfba4
23 Mar 21
GeoVax Reports 2020 Year-End Financial Results
4:35pm
8-K
loa3bi t8
11 Feb 21
GeoVax Announces Closing of $10.3 Million Bought Deal Offering
2:35pm
8-K
6fyvu8 pvxavt7ezdh
11 Feb 21
GeoVax Announces Pricing of $9.0 Million Bought Deal Offering
9:21am
8-K
6hiezq2ay3wrz4
30 Nov 20
GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development
5:18pm
8-K
js73ylwqd9 lb2lc
5 Nov 20
GeoVax Reports 2020 Third Quarter Financial Results
5:18pm
8-K
1oo9xfswk6gj6
26 Oct 20
GeoVax Announces License Agreement with NIH
5:28pm